Analyst Consensus ?
ConsensusBuy52 ratings
Bullish3975.0%
Neutral1223.1%
Bearish11.9%
FN2 Earnings Intelligence
Alnylam Pharmaceuticals, Inc. analyst ratings
Alnylam Pharmaceuticals, Inc. (ALNY) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$167.38Current
$96Low
$346.33Average
$570High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Needham | Buy | Buy | Maintain | Oct 29, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Oct 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Oct 14, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 8, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Sep 30, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Sep 21, 2026 |
| Jefferies | Hold | Hold | Maintain | Sep 8, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Aug 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | Aug 4, 2026 |
| Raymond James | Strong Buy | Outperform | Upgrade | Aug 3, 2026 |
| Barclays | Overweight | Overweight | Maintain | Aug 3, 2026 |
| Stifel | Buy | Buy | Maintain | Jul 31, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Jul 31, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| Chardan Capital | Buy | Buy | Maintain | Jul 31, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 14, 2026 |
| Freedom Capital Markets | Buy | Hold | Upgrade | Feb 17, 2026 |
| Freedom Broker | Buy | Hold | Upgrade | Feb 17, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Feb 17, 2026 |
| Leerink Partners | Market Perform | Market Perform | Maintain | Dec 15, 2025 |
| Piper Sandler | Overweight | Overweight | Maintain | Oct 31, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Sep 16, 2025 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Sep 11, 2025 |
| Wolfe Research | Peer Perform | Underperform | Upgrade | Aug 4, 2025 |
| UBS | Buy | Buy | Maintain | Aug 1, 2025 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Aug 1, 2025 |
| Bernstein | Outperform | Outperform | Maintain | Jan 7, 2025 |
| TD Cowen | Buy | Buy | Maintain | Oct 21, 2024 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Oct 11, 2024 |
| SMBC Nikko | Neutral | Neutral | Maintain | Apr 26, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Jan 23, 2023 |
| Guggenheim | Neutral | Buy | Downgrade | Jun 27, 2022 |
| William Blair | Outperform | Outperform | Maintain | Jun 7, 2022 |
| Nomura | Reduce | Reduce | Maintain | Apr 14, 2020 |
| Berenberg | Buy | Buy | Maintain | Mar 19, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 13, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Sep 3, 2019 |
| Stifel Nicolaus | Buy | Buy | Maintain | Apr 15, 2019 |
| Leerink Swann | Perform | Market Perform | Maintain | Nov 28, 2018 |
| Cowen & Co. | Outperform | Outperform | Maintain | Aug 13, 2018 |
| B. Riley Securities | Buy | Buy | Maintain | Aug 13, 2018 |
| B. Riley FBR | Buy | Buy | Maintain | Aug 13, 2018 |
| Credit Suisse | Outperform | Outperform | Maintain | Mar 13, 2018 |
| B. Riley | Buy | Buy | Maintain | Nov 8, 2017 |
| FBR Capital | Buy | Buy | Maintain | Nov 2, 2017 |
| Ladenburg Thalmann | Buy | Buy | Maintain | Feb 2, 2017 |
| Janney Capital | Neutral | Neutral | Maintain | Sep 29, 2016 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Mar 9, 2016 |
| PiperJaffray | Outperform | Outperform | Maintain | Jun 15, 2015 |
| S&P Capital IQ | Buy | Hold | Upgrade | Jan 27, 2014 |
| Deutsche Bank | Buy | Buy | Maintain | Sep 24, 2013 |
| McNicoll Lewis Vlak | Hold | Buy | Downgrade | Feb 9, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $167.38. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Stifel Nicolaus | Paul Matteis | $225 | $177.48 | +34.4% | Oct 29, 2026 |
| UBS | Joon Lee | $354 | $224.47 | +111.5% | Oct 15, 2026 |
| Wells Fargo | Derek Archila | $253 | $223.82 | +51.1% | Oct 14, 2026 |
| RBC Capital | Luca Issi | $345 | $222.62 | +106.1% | Oct 8, 2026 |
| Jefferies | Analyst unavailable | $260 | $266.11 | +55.3% | Sep 8, 2026 |
| Jefferies | Analyst unavailable | $230 | $233.5 | +37.4% | Aug 28, 2026 |
| Bernstein | Jeffrey Walch | $376 | $236.01 | +124.6% | Aug 25, 2026 |
| BMO Capital | Analyst unavailable | $318 | $228.61 | +90.0% | Aug 18, 2026 |
| Wells Fargo | Derek Archila | $256 | $227.12 | +52.9% | Aug 14, 2026 |
| H.C. Wainwright | Analyst unavailable | $455 | $215.61 | +171.8% | Aug 4, 2026 |
| Truist Financial | Analyst unavailable | $315 | $220.33 | +88.2% | Aug 4, 2026 |
| Barclays | Eliana Merle | $450 | $205.52 | +168.8% | Aug 3, 2026 |
| Raymond James | Martin Auster | $420 | $203.31 | +150.9% | Jul 31, 2026 |
| RBC Capital | Luca Issi | $350 | $203.29 | +109.1% | Jul 31, 2026 |
| Oppenheimer | Analyst unavailable | $350 | $205.48 | +109.1% | Jul 31, 2026 |
| Morgan Stanley | Analyst unavailable | $300 | $205.48 | +79.2% | Jul 31, 2026 |
| Stifel Nicolaus | Paul Matteis | $318 | $205.48 | +90.0% | Jul 31, 2026 |
| H.C. Wainwright | Analyst unavailable | $485 | $288.08 | +189.8% | Jul 13, 2026 |
| Truist Financial | Analyst unavailable | $410 | $298.76 | +144.9% | Jul 13, 2026 |
| Morgan Stanley | Analyst unavailable | $400 | $307.42 | +139.0% | Jul 10, 2026 |
| Raymond James | Analyst unavailable | $468 | $322.64 | +179.6% | Jul 9, 2026 |
| H.C. Wainwright | Analyst unavailable | $470 | $291.37 | +180.8% | Jun 29, 2026 |
| Morgan Stanley | Analyst unavailable | $370 | $301.45 | +121.0% | May 1, 2026 |
| Bernstein | Analyst unavailable | $447 | $302.85 | +167.0% | May 1, 2026 |
| Canaccord Genuity | Analyst unavailable | $429 | $314.4 | +156.3% | Feb 17, 2026 |
| Morgan Stanley | Analyst unavailable | $360 | $313.75 | +115.1% | Feb 13, 2026 |
| Bernstein | Analyst unavailable | $451 | $312.43 | +169.4% | Feb 13, 2026 |
| Chardan Capital | Analyst unavailable | $425 | $308.48 | +153.9% | Feb 13, 2026 |
| Stifel Nicolaus | Paul Matteis | $444 | $313.05 | +165.3% | Feb 12, 2026 |
| H.C. Wainwright | Analyst unavailable | $510 | $346.79 | +204.7% | Jan 30, 2026 |
| RBC Capital | Analyst unavailable | $465 | $359 | +177.8% | Jan 20, 2026 |
| Wells Fargo | Analyst unavailable | $376 | $359 | +124.6% | Jan 20, 2026 |
| Needham | Analyst unavailable | $529 | $398.29 | +216.0% | Jan 12, 2026 |
| Raymond James | Martin Auster | $472 | $398.29 | +182.0% | Jan 12, 2026 |
| Truist Financial | Analyst unavailable | $530 | $419.08 | +216.6% | Jan 8, 2026 |
| Bernstein | Analyst unavailable | $491 | $387.44 | +193.3% | Jan 6, 2026 |
| Leerink Partners | Mani Foroohar | $351 | $399.42 | +109.7% | Dec 15, 2025 |
| Stifel Nicolaus | Analyst unavailable | $508 | $404.46 | +203.5% | Dec 11, 2025 |
| H.C. Wainwright | Patrick Trucchio | $570 | $434.07 | +240.5% | Nov 4, 2025 |
| Barclays | Analyst unavailable | $527 | $449.56 | +214.8% | Oct 31, 2025 |
| Oppenheimer | Leland Gershell | $500 | $449.56 | +198.7% | Oct 31, 2025 |
| Chardan Capital | Keay Nakae | $475 | $449.56 | +183.8% | Oct 31, 2025 |
| UBS | Analyst unavailable | $549 | $449.56 | +228.0% | Oct 30, 2025 |
| Morgan Stanley | Michael Ulz | $495 | $449.56 | +195.7% | Oct 30, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $450 | $474 | +168.8% | Oct 22, 2025 |
| Truist Financial | Analyst unavailable | $535 | $479.18 | +219.6% | Oct 17, 2025 |
| Morgan Stanley | Michael Ulz | $475 | $456.35 | +183.8% | Oct 6, 2025 |
| Stifel Nicolaus | Paul Matteis | $495 | $456.35 | +195.7% | Oct 6, 2025 |
| BMO Capital | Kostas Biliouris | $470 | $452.81 | +180.8% | Sep 5, 2025 |
| Raymond James | Analyst unavailable | $370 | $330.55 | +121.0% | Jul 29, 2025 |
| Truist Financial | Danielle Brill | $385 | $324.49 | +130.0% | Jul 21, 2025 |
| BMO Capital | Kostas Biliouris | $360 | $325 | +115.1% | Jun 24, 2025 |
| Scotiabank | Analyst unavailable | $338 | $283.34 | +101.9% | Mar 21, 2025 |
| Bernstein | William Pickering | $310 | $235.95 | +85.2% | Jan 7, 2025 |
| Canaccord Genuity | Whitney Ijem | $336 | $294.87 | +100.7% | Oct 24, 2024 |
| Canaccord Genuity | Whitney Ijem | $366 | $273.69 | +118.7% | Oct 1, 2024 |
| Bank of America Securities | Tazeen Ahmad | $307 | $274.91 | +83.4% | Sep 27, 2024 |
| BMO Capital | Kostas Biliouris | $300 | $269.31 | +79.2% | Aug 27, 2024 |
| RBC Capital | Luca Issi | $300 | $271.42 | +79.2% | Aug 26, 2024 |
| Goldman Sachs | Salveen Richter | $370 | $262.7 | +121.0% | Aug 16, 2024 |
| Canaccord Genuity | Whitney Ijem | $357 | $253.86 | +113.3% | Jul 8, 2024 |
| UBS | Esther Rajavelu | $288 | $247 | +72.1% | Jun 28, 2024 |
| RBC Capital | Luca Issi | $265 | $245.17 | +58.3% | Jun 27, 2024 |
| Stifel Nicolaus | Paul Matteis | $295 | $247.4 | +76.2% | Jun 27, 2024 |
| Evercore ISI | Liisa Bayko | $260 | $222.9 | +55.3% | Jun 25, 2024 |
| RBC Capital | Luca Issi | $250 | $222.9 | +49.4% | Jun 25, 2024 |
| Morgan Stanley | Andrew Galler | $250 | $224.7 | +49.4% | Jun 24, 2024 |
| H.C. Wainwright | Patrick Trucchio | $400 | $227.05 | +139.0% | Jun 24, 2024 |
| Stifel Nicolaus | Paul Matteis | $247 | $227.92 | +47.6% | Jun 24, 2024 |
| RBC Capital | Luca Issi | $235 | $156.43 | +40.4% | Jun 12, 2024 |
| BMO Capital | Kostas Biliouris | $234 | $156.59 | +39.8% | Apr 8, 2024 |
| Piper Sandler | Edward Tenthoff | $253 | $229.37 | +51.1% | Dec 15, 2022 |
| Cantor Fitzgerald | Olivia Brayer | $175 | $145.85 | +4.5% | Jul 12, 2022 |
| Piper Sandler | Edward Tenthoff | $208 | $135.82 | +24.3% | Jun 14, 2022 |
| H.C. Wainwright | Analyst unavailable | $430 | $133.43 | +156.9% | May 2, 2022 |
| BMO Capital | Analyst unavailable | $166 | $137.8 | -0.8% | Apr 29, 2022 |
| Citigroup | Analyst unavailable | $211 | $136.67 | +26.1% | Apr 29, 2022 |
| Leerink Partners | Analyst unavailable | $96 | $143.16 | -42.6% | Apr 29, 2022 |
| Morgan Stanley | Analyst unavailable | $178 | $167 | +6.3% | Apr 25, 2022 |
| Berenberg Bank | Zhiqiang Shu | $154 | $150.76 | -8.0% | Feb 11, 2022 |
| BMO Capital | Gary Nachman | $175 | $150.76 | +4.5% | Feb 11, 2022 |
| RBC Capital | Luca Issi | $225 | $150.86 | +34.4% | Feb 10, 2022 |
| Guggenheim | Debjit Chattopadhyay | $170 | $142.51 | +1.6% | Feb 3, 2022 |
| Bank of America Securities | Tazeen Ahmad | $209 | $130.12 | +24.9% | Jan 26, 2022 |
| Jefferies | Maury Raycroft | $205 | $136.53 | +22.5% | Jan 23, 2022 |
| Cowen & Co. | Ritu Baral | $250 | $186.42 | +49.4% | Dec 13, 2021 |
| Goldman Sachs | Salveen Richter | $273 | $187.01 | +63.1% | Nov 22, 2021 |
| Cantor Fitzgerald | Alethia Young | $275 | $159.56 | +64.3% | Oct 29, 2021 |
| UBS | Esther Rajavelu | $211 | $159.56 | +26.1% | Oct 29, 2021 |
| Evercore ISI | Maneka Mirchandaney | $190 | $159.56 | +13.5% | Oct 29, 2021 |
| Barclays | Gena Wang | $210 | $162.14 | +25.5% | Oct 28, 2021 |
Track every rating change on ALNY the moment it posts. Free to start.
Start freeGet the ALNY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.